OIVD Needs a Consumer Genetics Game Plan, and Fast

Absent a game plan for regulating such tests, the agency's rationale for launching an investigation into Pathway's service is akin to crying "FDA knows best" without any supporting evidence.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.